Immunosuppressive regimen and risk for de novo malignancies after liver transplantation for alcoholic liver disease - 18/10/18
, Delphine Maucort-Boulch b, c, Domitille Poinsot a, b, Elsa Thimonier a, b, Christine Chambon-Augoyard a, Emilie Ducroux d, Mélanie Vallin a, Thomas Walter a, b, Philip Robinson e, Olivier Guillaud a, Olivier Boillot a, bBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 9 |
| Iconographies | 5 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | Alcoholic liver disease is the main indication for liver transplantation in France and one of the main indications worldwide. |
• | De novo malignancies after liver transplantation for alcoholic liver disease is a frequent and life-threatening long-term complication. |
• | The main risk factor for de novo malignancies after liver transplantation for alcoholic liver disease is tobacco smoking (both past and active). |
• | Using mTOR inhibitor-based immunosuppressive regimen could reduce this risk for de novo malignancies after liver transplantation for alcoholic liver disease. |
Summary |
Background and aims |
Long-term prognosis after liver transplantation for alcoholic liver disease is impaired because of the occurrence of de novo malignancies and recurrent disease on liver graft. The aim of the present retrospective study was to evaluate the risk of de novo malignancy and to identify the predictive factors in a large cohort of liver-transplanted patients with a long follow-up in the setting of alcoholic liver disease.
Methods |
All patients who underwent a first liver transplantation for alcoholic liver disease in our centre, from December 1985 to October 2010, and who survived more than 6 months were included. Survival, incidence of de novo malignancies and several clinical and biological parameters were studied.
Results |
The study population consisted in 368 patients (284 males, median age 52.6 years). The cumulative incidence of a first solid organ de novo malignancy after LT was 8.7% at 5 years, 22.3% at 10 years, 31.5% at 15 years, and 33.1% at 20 years. Tobacco use (both past and current) was associated with a significant increased risk of de novo solid organ malignancy (HR 3.35 and 4.62, respectively), whereas immunosuppressive regimen including mTOR inhibitors (mTORi) was associated with a decreased risk (post-transplant time under mTORi-including immunosuppressive regimen was significantly longer in patients who did not present de novo malignancy (10.6% vs. 2.3%, P=1.4×10−5)).
Conclusions |
Our study provides additional evidence that de novo malignancies in alcoholic liver disease liver transplant patients is a major long-term complication, and that conversion from to an mTORi-including immunosuppressive regimen could reduce this risk.
Le texte complet de cet article est disponible en PDF.Keywords : Liver transplantation, Alcoholic cirrhosis, Cancer, Survival
Abbreviations : LT, CNI, MMF
Plan
Vol 42 - N° 5
P. 427-435 - octobre 2018 Retour au numéro
Article précédent
- Predictive value of liver damage for severe early complications and survival after heart transplantation: A retrospective analysis
- Pascal Lebray, Shaida Varnous, Alina Pascale, Philippe Leger, Charles Edouard Luyt, Vlad Ratziu, Mona Munteanu, Salima Ould Amar, Dominique Thabut, Jean Chastre, Alain Pavie, Thierry Poynard, Pascal Leprince
- Association between appendectomy and risk of primary sclerosing cholangitis: A systematic review and meta-analysis
- Karn Wijarnpreecha, Panadeekarn Panjawatanan, Omar Y. Mousa, Wisit Cheungpasitporn, Surakit Pungpapong, Patompong Ungprasert
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?